BR9910112A - Métodos para a inibição de mrp1 - Google Patents

Métodos para a inibição de mrp1

Info

Publication number
BR9910112A
BR9910112A BR9910112-2A BR9910112A BR9910112A BR 9910112 A BR9910112 A BR 9910112A BR 9910112 A BR9910112 A BR 9910112A BR 9910112 A BR9910112 A BR 9910112A
Authority
BR
Brazil
Prior art keywords
methods
mrp1
inhibiting mrp1
inhibiting
inhibition
Prior art date
Application number
BR9910112-2A
Other languages
English (en)
Inventor
Joseph Michael Gruber
Julian Stanley Kroin
Bryan Hurst Norman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR9910112A publication Critical patent/BR9910112A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of The Air-Fuel Ratio Of Carburetors (AREA)
  • Magnetically Actuated Valves (AREA)

Abstract

Patente de Invenção: <B>"MéTODOS PARA A INIBIçãO DE MRP1"<D>. A presente invenção refere-se a um composto da fórmula (I), que é útil para a inibição de neoplasmas resistentes onde a resistência é conferida em parte ou no total por MRP1.
BR9910112-2A 1998-04-08 1999-04-07 Métodos para a inibição de mrp1 BR9910112A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8108098P 1998-04-08 1998-04-08
PCT/US1999/007613 WO1999051228A1 (en) 1998-04-08 1999-04-07 Methods for inhibiting mrp1

Publications (1)

Publication Number Publication Date
BR9910112A true BR9910112A (pt) 2000-12-26

Family

ID=22161981

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910112-2A BR9910112A (pt) 1998-04-08 1999-04-07 Métodos para a inibição de mrp1

Country Status (18)

Country Link
US (1) US6369070B1 (pt)
EP (1) EP1067928A4 (pt)
JP (1) JP2002510625A (pt)
KR (1) KR20010042471A (pt)
CN (1) CN1304306A (pt)
AU (1) AU3476999A (pt)
BR (1) BR9910112A (pt)
CA (1) CA2327617A1 (pt)
EA (1) EA200001034A1 (pt)
HR (1) HRP20000646A2 (pt)
HU (1) HUP0101508A3 (pt)
ID (1) ID27364A (pt)
IL (1) IL138389A0 (pt)
NO (1) NO20005023L (pt)
PL (1) PL343313A1 (pt)
SK (1) SK14982000A3 (pt)
TR (1) TR200002851T2 (pt)
WO (1) WO1999051228A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027116A2 (en) * 1999-10-07 2001-04-19 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
AU2251901A (en) * 1999-12-22 2001-07-03 Eli Lilly And Company Methods and compounds for inhibiting MRP1
AU7489101A (en) 2000-06-14 2001-12-24 Lilly Co Eli Tricyclic compounds as mrp1-inhibitors
AU2001294518A1 (en) * 2000-09-22 2002-04-02 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
WO2002081481A1 (en) * 2001-04-09 2002-10-17 Eli Lilly And Company Compounds and methods for inhibiting mrp1
US7101891B2 (en) 2001-04-09 2006-09-05 Eli Lilly And Company Compounds and pharmaceutical compositions for inhibiting MRP1
ATE311392T1 (de) * 2001-04-09 2005-12-15 Lilly Co Eli Verbindungen und methoden zur inhibierung von mrp1
WO2005048948A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
KR20070034993A (ko) * 2004-05-14 2007-03-29 아이알엠 엘엘씨 Ｐｐａｒ 조절제로서의 화합물 및 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588731A (en) * 1985-06-21 1986-05-13 Roussel Uclaf Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of preparation and use as anxiolytic agents
US5744485A (en) * 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity

Also Published As

Publication number Publication date
IL138389A0 (en) 2001-10-31
US6369070B1 (en) 2002-04-09
JP2002510625A (ja) 2002-04-09
AU3476999A (en) 1999-10-25
EA200001034A1 (ru) 2001-04-23
CN1304306A (zh) 2001-07-18
EP1067928A1 (en) 2001-01-17
KR20010042471A (ko) 2001-05-25
HUP0101508A3 (en) 2002-04-29
HUP0101508A2 (hu) 2001-10-28
NO20005023D0 (no) 2000-10-05
EP1067928A4 (en) 2001-11-14
CA2327617A1 (en) 1999-10-14
HRP20000646A2 (en) 2001-06-30
TR200002851T2 (tr) 2000-12-21
SK14982000A3 (sk) 2001-05-10
PL343313A1 (en) 2001-08-13
WO1999051228A1 (en) 1999-10-14
ID27364A (id) 2001-04-05
NO20005023L (no) 2000-12-05

Similar Documents

Publication Publication Date Title
DE60025744D1 (de) Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
BR0109851A (pt) Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BR0203538A (pt) Estabilização de polìmeros sintéticos
BR9507995A (pt) Composto uso do composto formulação farmacêutica intermediário e processos para a preparação de um composto e de intermediário e para tratamento de uma condição em que existe uma vantagem em inibir a produção de no a partir de l-arginina pela ação de no sintase
BR0206670A (pt) Compostos halogenados que exibem agonismo para receptor de trombopoietina
ES2155219T3 (es) Compuestos nucleotidos de fosfonato.
BR9910112A (pt) Métodos para a inibição de mrp1
BR0206738A (pt) Derivados tricìclicos de lactama e de sultama e uso dos mesmos como inibidores de histona desacetilase
DE60332562D1 (de) Therapeutische Piperazinverbindungen
BR9900788A (pt) Compostos ésteres.
BR9814832A (pt) Composto, e, herbicida
BR0113389A (pt) Compostos que inibem a atividade do fator xa
BR9811273A (pt) Derivados de benzimidazol
PT1250340E (pt) Metodos e compostos para inibicao de mrp1
BR0317284A (pt) Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BR9909497A (pt) Métodos para inibição da mrp1
BR9909446A (pt) Métodos para inibição de mrp1
BR0107978A (pt) Cera de vela estabilizada por uma combinação de absorvente de radiação uv mais uma amina impedida selecionada
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
BR9916807A (pt) Antagonistas de 5ht1 para terapia antidepressiva
NO20015600L (no) Anvendelse av 1,4-benzotiazepin-derivater som legemidler for å overvinne resistens mot anticancer legemidler
DK1054869T3 (da) 3,4-Dihydroquinolin-derivater som inhibitorer for nitrogenmonoxid-synthase (NOS)
BR0016274A (pt) Preparações de pigmentos aperfeiçoadas referente aos regulamentos de segurança

Legal Events

Date Code Title Description
FA10 Dismissal: dismissal - article 33 of industrial property law
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]